Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1021-1027 , November 2006

In vitro and in vivo evaluation of [11C]MPEPy as a potential PET ligand for mGlu5 receptors

  • Alin J. Severance

      Affiliations

    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA
    • ,
  • Ramin V. Parsey

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. New York State Psychiatric Institute, Box #42, New York, NY 10032, USA. Tel.: +1 212 543 6101; fax: +1 212 543 6017.
    • ,
  • J.S. Dileep Kumar

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA
    • ,
  • Mark D. Underwood

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA
    • ,
  • Victoria Arango

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA
    • ,
  • Vattoly J. Majo

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • ,
  • Jaya Prabhakaran

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • ,
  • Norman R. Simpson

      Affiliations

    • Department of Radiology, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • ,
  • Ronald L. Van Heertum

      Affiliations

    • Department of Radiology, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • ,
  • J. John Mann

      Affiliations

    • Department of Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Department of Radiology, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    • Division of Brain Imaging, Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032, USA

Received 2 September 2006 ,Accepted 28 September 2006.

References 

  1. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 1994;17:31–108
  2. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 1992;258(5082):597–603
  3. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997;37:205–237
  4. Fitzjohn SM, Irving AJ, Palmer MJ, Harvey J, Lodge D, Collingridge GL. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci Lett. 1996;203(3):211–213
  5. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132(7):1423–1430
  6. Wieronska JM, Branski P, Szewczyk B, Palucha A, Papp M, Gruca P, et al. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol J Pharmacol. 2001;53(6):659–662
  7. Smialowska M, Szewczyk B, Branski P, Wieronska JM, Palucha A, Bajkowska M, et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology. 2002;42(8):1016–1023
  8. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001;40(1):1–9
  9. Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology. 2001;40(1):10–19
  10. Sotgiu ML, Bellomi P, Biella GE. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci Lett. 2003;342(1–2):85–88
  11. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295(3):1267–1275
  12. Schulz B, Fendt M, Gasparini F, Lingenhohl K, Kuhn R, Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology. 2001;41(1):1–7
  13. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wislowska A, et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol. 2005;514(1):25–34
  14. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 2001;4(9):873–874
  15. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther. 2000;88(3):427–435
  16. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology. 2001;41(4):413–420
  17. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci. 2002;22(13):5669–5678
  18. Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging. 2003;20(5):377–397
  19. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett. 1993;163(1):53–57
  20. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol. 1995;355(3):455–469
  21. Anderson JJ, Rao SP, Rowe B, Giracello DR, Holtz G, Chapman DF, et al. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002;303(3):1044–1051
  22. Anderson JJ, Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Roppe J, et al. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine. Eur J Pharmacol. 2003;473(1):35–40
  23. Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, et al. [3H]-Methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett. 2003;13(3):351–354
  24. Patel S, Krause SM, Hamill T, Chaudhary A, Burns DH, Gibson RA. In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand. Life Sci. 2003;73(3):371–379
  25. Yu M, Tueckmantel W, Wang X, Zhu A, Kozikowski AP, Brownell AL. Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors. Nucl Med Biol. 2005;32(6):631–640
  26. Maclver MB, Mikulec AA, Amagasu SM, Monroe FA. Volatile anesthetics depress glutamate transmission via presynaptic actions. Anesthesiology. 1996;85(4):823–834
  27. Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med. 2003;348(21):2110–2124
  28. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse. 2005;56(4):205–216
  29. Jewett DM. A simple synthesis of [11C]carfentanil using an extraction disk instead of HPLC. Nucl Med Biol. 2001;28(6):733–734
  30. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38(10):1493–1503
  31. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed.. San Diego: Academic Press; 1986;
  32. Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC. Automated image registration: I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr. 1998;22(1):139–152
  33. Woods RP, Grafton ST, Watson JD, Sicotte NL, Mazziotta JC. Automated image registration: II. Intersubject validation of linear and nonlinear models. J Comput Assist Tomogr. 1998;22(1):153–165
  34. Watson CC, Newport D, Casey ME. A single scatter simulation technique for scatter correction in 3D PET. In:  Grangeat P,  Amans JL editor. Fully three-dimensional image reconstruction in radiology and nuclear medicine. France: Aix-les-bains; 1995;p. 215–219
  35. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034–1057
  36. Spooren WP, Gasparini F, Salt TE, Kuhn R. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci. 2001;22(7):331–337
  37. Patel S, Ndubizu O, Hamill T, Chaudhary A, Burns HD, Hargreaves R, et al. Screening cascade and development of potential Positron Emission Tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol Imaging Biol. 2005;7(4):314–323
  38. Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 1: General considerations. Experientia. 1986;42(2):109–114
  39. Hara K, Harris RA. The anesthetic mechanism of urethane: the effects on neurotransmitter-gated ion channels. Anesth Analg. 2002;94(2):313–318
  40. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic–ischemic neuronal death. Annu Rev Neurosci. 1990;13:171–182
  41. Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and p-glycoprotein function in the rodent brain. Mol Imaging Biol. 2005;7(1):37–44
  42. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med. 2006;47(4):698–705

PII: S0969-8051(06)00194-6

doi: 10.1016/j.nucmedbio.2006.09.007

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1021-1027 , November 2006

Article Tools

* Image Usage & Resolution